# **Amiodarone-Induced Thyrotoxicosis**



Ricardo Fonseca, Catarina Roque, Carlos Bello, Francisco Sousa Santos, Ricardo Capitão, João Sequeira Duarte, Carlos Vasconcelos ENDOCRINOLOGY DEPARTMENT | HOSPITAL EGAS MONIZ (CHLO) | LISBON, PORTUGAL

#### **BACKGROUND**

Amiodarone is an antiarrhytmic drug mainly used in atrial fibrillation. Amiodarone-induced thyrotoxicosis (AIT) is less common than hypothyroidism, but it represents a true therapeutic challenge. AIT can be due iodine load (type 1) or a destructive thyroiditis (type 2).

### **METHODS**


Retrospective study of patients with AIT, diagnosed between 2010 and 2015, in a central hospital. We reviewed medical records regarding age, gender, amiodarone therapy, hospitalizations, cardiovascular events, thyroid function and therapy. We used descriptive statistics, t-test for continuous variables and chi-squared distribution for categorical variables.


## RESULTS







Gender









Symptons and signals

62,5%


12,5%


4%


4%


3%

14%











Presentation







	Resolution
<b>√</b>	Medication 70%
$\checkmark$	Radiodine 2,5% (TA)
<b>√</b>	Surgery 5% (GD)
	<u>Events</u>
Ca	rdiovascular events 10
	Hospitalizations 14
	Mortality 3

Workup

## Conclusion

AIT is a concern in elderly people, because treatment is challenging. Patients treated with Amiodarona and AIT need frequent hospitalizations.

Type 2 AIT was the most frequent (62,5%), with higher FT4 (p=0,014), but treatment duration was smaller (p<0,001).



